The scientific community is currently seeing great advancements in targeted approaches that have led to a wave of new treatments for patients that consider each patient’s underlying genetics and what makes each patient’s cancer unique. In 2020 alone, the FDA approved 19 targeted treatments, accounting for 39% of new drug approvals.1
As part of this scientific revolution, scientists have pursued a targeted treatment over the last 40 years for patients with the KRAS-mutation – which has been deemed one of cancer’s toughest challenges.
While research efforts have been able to identify and develop treatments for other driver gene mutations that contribute to cancer growth, success with targeting KRAS, the most frequently mutated variant of the RAS family, has remained unreachable.2
One of the most frequent KRAS mutations is KRAS G12C,3 a fundamental driver of many human cancers including 13% of patients with non-small cell lung cancer (NSCLC).4 For those with KRAS G12C, there have been no targeted treatment options and, tragically, poor outcomes.
But now, the latest in cancer research brings new hope, as KRAS G12C is now actionable!
Amgen has discovered an innovative approach to targeting KRASG12C that focuses on features of the mutant protein that normal KRAS lacks and offers a new targeted treatment option for patients with this mutation. In this video, learn more about the Amgen discovery, what this means for patients and the unique story behind a newly actionable biomarker for patients with NSCLC that has become the fastest development program in Amgen’s history.
1 Personalized Medicine Coalition. Personalized Medicine at FDA. Available at: http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PM_at_FDA_The_Scope_Significance_of_Progress_in_2020.pdf?_zs=02X7b&_zl=ihuQ2. Accessed 5/5/21.
2 Cox AD, et al. Nat Rev Drug Discov. 2014;13:828-851.
3 Liu P, et al. Acta Pharm Sin B. 2019;9:871-879.
4 Amgen, Data on File. 2020.